Skip to content

SHERLOCK 3CG™ Diamond Tip Confirmation System

A Single-Arm Prospective, Multi-Centered Study to Assess the SHERLOCK 3CG™ Diamond Tip Confirmation System

Status
Terminated
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03288766
Acronym
MODUS II
Enrollment
232
Registered
2017-09-20
Start date
2018-04-19
Completion date
2021-06-15
Last updated
2021-10-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atrial Flutter, Atrioventricular Block, Bundle-Branch Block, Indication for Peripheral Intravenous Catheterization, Premature Atrial Contraction, Premature Junctional Contraction, Premature Ventricular Contraction, Tachycardia

Brief summary

This study is a single-arm, prospective, multi-center study to assess clinical performance of the SHERLOCK 3CG™ Diamond Tip Confirmation System (TCS) with MODUS II software for confirming correct tip position of peripherally inserted central catheters (PICCs) in adult subjects with altered cardiac rhythm.

Detailed description

This study is intended to confirm the accuracy of the SHERLOCK 3CG™ Diamond TCS with the addition of MODUS II (SLM2) software to eliminate the need for post-procedural chest x-ray (CXR) in adult subjects with cardiac abnormalities that alter presentation of the P-wave. Atrial fibrillation will be the primary target while data on pacemaker driven rhythms and other arrhythmia types will also be collected to explore overall performance.

Interventions

PROCEDUREPICC placement with SHERLOCK 3CG™ Diamond TCS with MODUS II software

The SHERLOCK 3CG™ Diamond Tip Confirmation System (TCS) is an FDA-cleared fully-integrated magnetic tracking and ECG-based PICC tip confirmation technology, indicated for use as an alternative to chest x-ray and fluoroscopy for PICC tip placement confirmation in adult patients without any alterations of cardiac rhythms that change the normal presentation of the P-wave. A software package, MODUS II, has been developed to accurately analyze the entire ECG complex and identify the correct placement of the PICC tip based on a patient's individual ECG, in the absence of an easily identifiable P-wave. This software system is designed to provide visual and/or audio cues to notify the PICC placer of the location of the PICC tip relative to the cavoatrial junction (CAJ) of the patient.

Sponsors

C. R. Bard
Lead SponsorINDUSTRY

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
21 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Male or female, ≥ 21 years of age with altered cardiac rhythm (no recognizable P-wave on standard ECG) with diagnosis of specific arrhythmia type or identification of pacemaker driven rhythms as defined below: 1. Atrial fibrillation with history of diagnosis per 12-lead ECG in medical record or diagnosed via bedside telemetry by study team RN at assessment, or 2. All other arrhythmias (including but not limited to atrial flutter, PAC, PVC, PJC, tachycardia, AV Block, BB Block) with history of diagnosis per 12-lead ECG in medical record or diagnosed via bedside telemetry by cardiac unit RN at assessment, or retrospectively by site cardiologist, or 3. Pacemaker driven rhythm with temporary or permanent pacemaker device in place; * Subject requires PICC placement as part of standard of care; * Subject or Legally Authorized Representative (LAR) has signed an Informed Consent Form (ICF).

Exclusion criteria

* Subject has a contraindication to PICC placement as listed in the Instructions for Use (IFU) to include: 1. The presence of bacteremia or septicemia (known or suspected), 2. The patient's body size is insufficient to accommodate the size of the implanted device, 3. The patient is known or is suspected to be allergic to materials contained in the device, 4. Past irradiation of prospective insertion site, 5. Previous episodes of venous thrombosis or vascular surgical procedures at the prospective placement site, 6. Local tissue factors will prevent proper device stabilization and/or access; * Subjects who previously had a PICC in place and require a PICC exchange; * Subject has presence of active resting tremor (i.e. Parkinson's, Multiple Sclerosis, etc.) deemed by Investigator to have potential impact on procedure accuracy; * Subjects who are pregnant or think they may be pregnant.

Design outcomes

Primary

MeasureTime frameDescription
Rate of successful PICC tip placement within the lower third of the superior vena cava (SVC) or in the cavoatrial junction (CAJ) using SLM2The PICC insertion procedure is 60-90 mins in durationTip positioning is determined at bedside by the software via the Green Diamond Indicator (GDI+) and confirmed by CXR. PICC tip placement will be considered successful if it is determined to be in the lower 1/3 of the SVC or in the CAJ by an independent, blinded radiologist judging position retrospectively against pre-specified anatomical criteria.

Secondary

MeasureTime frameDescription
Rate of successful PICC tip placement within the lower third of the superior vena cava (SVC) or in the cavoatrial junction (CAJ) using SLM2 in the absence of a GDIThe PICC insertion procedure is 60-90 mins in durationIt is expected there will be some cases where the MODUS II software may fail to present a Green Diamond Indicator (GDI-). In the absence of a GDI, tip positioning is determined at bedside using magnetic tracking and external measurement per hospital protocol, with CXR required for tip confirmation. PICC tip placement will be considered successful if it is determined to be in the lower 1/3 of the SVC or in the CAJ by an independent, blinded radiologist judging position retrospectively against pre-specified anatomical criteria.
Percent agreement between the site readings of the CXR (standard of care) versus those completed by an independent, blinded radiologistThe PICC insertion procedure is 60-90 mins in durationAn independent, blinded radiologist will judge PICC tip position retrospectively against pre-specified anatomical criteria compared with findings of the SLM2.

Countries

Australia, United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026